Developing gene editing technologies for new drugs and plant-based biopharmaceuticals. It focuses on CRISPR-CasN enzymes and CRISPR gene editing to create innovative solutions in healthcare and agriculture. The offerings include CRISPR genome editing, CRISPR services, and protein synthesis. They are developing new drugs, plant-based biopharmaceuticals, and novel crop varieties enriched with vitamins and nutrients. It utilizes platforms like Cancerase for cancer therapeutics and PDB for plant-bas Founded in 2014, headquartered in Cheongju-si, South Korea. The company has raised $12M at the Series C stage backed by investors including Smile Gate Investment, Chong Kun Dang Pharmaceutical, Alpen Route, ActnerLab, E&Investment. Operating in Life Sciences > Life Sciences Platforms and Tools, Food and Agriculture Tech > Crop Tech.
G + FLAS Life Sciences
Series CDeveloping gene editing technologies for new drugs and plant-based biopharmaceuticals. It focuses on CRISPR-CasN enzymes and CRISPR gene editing to create innovative solutions in healthcare and agriculture. The offerings include CRISPR genome editing, CRISPR services, and protein synthesis. They are developing new drugs, plant-based biopharmaceuticals, and novel crop varieties enriched with vitamins and nutrients.…
About
Business model
Genomics > Enabling Technologies > Technology Platforms > Gene Editing,
Life Sciences Platforms and Tools > Research Services > Diversified,
Crop Tech > Farm Inputs > Plant Breeding > Technology Providers
Institutional investors
Latest coverage
📰 Latest funding news — recent raises and deal signals across the ecosystem.
Backed by funds in our directory
🗂️ Browse all funds in our directory — active VCs and growth investors by stage and sector.
Similar startups
Raising like G + FLAS Life Sciences?
Analyze your pitch deck before your next raise.
Analyze My Deck →